全文获取类型
收费全文 | 141796篇 |
免费 | 10377篇 |
国内免费 | 3961篇 |
专业分类
耳鼻咽喉 | 1046篇 |
儿科学 | 2413篇 |
妇产科学 | 2096篇 |
基础医学 | 8301篇 |
口腔科学 | 3138篇 |
临床医学 | 16822篇 |
内科学 | 21651篇 |
皮肤病学 | 2393篇 |
神经病学 | 6991篇 |
特种医学 | 4488篇 |
外国民族医学 | 39篇 |
外科学 | 17725篇 |
综合类 | 20334篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5870篇 |
眼科学 | 2088篇 |
药学 | 11217篇 |
90篇 | |
中国医学 | 11282篇 |
肿瘤学 | 18125篇 |
出版年
2024年 | 341篇 |
2023年 | 2530篇 |
2022年 | 4703篇 |
2021年 | 6359篇 |
2020年 | 6090篇 |
2019年 | 5397篇 |
2018年 | 5122篇 |
2017年 | 5376篇 |
2016年 | 5659篇 |
2015年 | 5489篇 |
2014年 | 10177篇 |
2013年 | 12460篇 |
2012年 | 8185篇 |
2011年 | 8847篇 |
2010年 | 7338篇 |
2009年 | 6789篇 |
2008年 | 6625篇 |
2007年 | 6924篇 |
2006年 | 6212篇 |
2005年 | 5481篇 |
2004年 | 4486篇 |
2003年 | 4008篇 |
2002年 | 3297篇 |
2001年 | 2873篇 |
2000年 | 2408篇 |
1999年 | 1882篇 |
1998年 | 1573篇 |
1997年 | 1331篇 |
1996年 | 1108篇 |
1995年 | 1012篇 |
1994年 | 803篇 |
1993年 | 635篇 |
1992年 | 558篇 |
1991年 | 487篇 |
1990年 | 429篇 |
1989年 | 379篇 |
1988年 | 379篇 |
1987年 | 334篇 |
1986年 | 255篇 |
1985年 | 299篇 |
1984年 | 277篇 |
1983年 | 199篇 |
1982年 | 203篇 |
1981年 | 192篇 |
1980年 | 165篇 |
1979年 | 146篇 |
1978年 | 83篇 |
1977年 | 54篇 |
1976年 | 62篇 |
1975年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
雌激素及其受体与胆囊癌关系的研究现状及进展 总被引:2,自引:0,他引:2
目的:探讨并讨论雌激素及其抗体与胆囊癌的关系.方法:阅读关于雌激素和胆囊癌方面的文献并进行总结.结果:雌激素在胆囊癌转变过程中起极为重要的作用.结论:研究胆囊癌患者血清中的雌激素水平对胆囊癌的发生、发展、预后及指导相应临床内分泌治疗具有重要的理论意义. 相似文献
72.
Venous and arterial thrombosis are closely related to many severe diseases, especially to cardiovascular and cerebrovasular disorders. Thrombolytic therapy has been proven to be an effective method to treat such disease, which decreased the mortality and morbidity greatly. 相似文献
73.
阿米替林合并认知疗法治疗精神分裂症后抑郁的对照研究 总被引:4,自引:0,他引:4
目的 评价阿米替林合并认知疗法对精神分裂症后抑郁的治疗效果。方法 将符合CCMD 3诊断标准的 86例精神分裂症后抑郁患者随机分为治疗组和对照组 ,治疗组给予阿米替林合并认知治疗 ,对照组织给予阿米替林治疗 ,疗程 12周。采用汉密尔顿抑郁量表 (HAMD)、简明精神病量表(BPRS)、阴性症状量表 (SANS)评定临床疗效 ,采用副反应量表 (TESS)评定副反应。结果 在治疗的 4、8、12周末 ,HAMD评分治疗组优于对照组 ,显效率分别为 83 95 %和 6 1 90 % (u =5 .83,P <0 0 5 )。结论 阿米替林与认知治疗组结合治疗精神分裂症后抑郁疗效好于单用阿米替林治疗。 相似文献
74.
Paul Roderick Ruth Davies Chris Jones Terry Feest Steve Smith Ken Farrington 《Nephrology, dialysis, transplantation》2004,19(3):692-701
BACKGROUND: The demand for renal replacement therapy (RRT) in England has risen steadily, although from a lower base than many other developed countries. Predicting the future demand for RRT and the impact of factors such as the acceptance rate, transplant supply and patient survival, is required in order to inform the planning of such services. METHODS: A discrete event simulation model estimates the future demand for RRT in England in 2010 for a range of scenarios. The model uses current prevalence and current and projected future acceptance rates, survival rates and the transitions between modalities to predict future patient numbers. National population and mortality data, published literature and data from the UK Renal Registry and UK Transplant, are used to estimate unmet need for RRT, the impact of changing demography and incidence of Type 2 diabetes, patient haemodialysis (HD) survival and transplant supply. RESULTS: By 2010 the predicted prevalence will have increased from about 30,000 in 2000 to between 42 and 51,000 (900-1000 p.m.p.), an average annual growth of 4.5-6%. Changing transplant supply has a small effect on overall numbers but changes the proportion of patients with functioning graft by up to 8%. Even with an optimistic increase in transplant supply (11% p.a. for 5 years), numbers on HD will continue to rise substantially, especially in the elderly. The factors most influencing future patient numbers are the acceptance rate and dialysis survival. CONCLUSION: This model predicts a substantial growth in the RRT population to 2010 to a rate approaching 1000 p.m.p., particularly in the elderly and those on HD, with a steady state not being reached for at least 25 years. 相似文献
75.
Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer 总被引:2,自引:0,他引:2
MIZUKI ONOZAWA KOJI KAWAI TAKAHIRO YAMAMOTO SHIRO HINOTSU SADAMU TSUKAMOTO KAZUNORI HATTORI NAOTO MIYANAGA TORU SHIMAZUI HIDEYUKI AKAZA 《International journal of urology》2004,11(7):535-541
BACKGROUND: Since the advent of cisplatin-based chemotherapy, the majority of metastatic testicular cancers can be cured by chemotherapy followed by retroperitoneal lymph node dissection (RPLND). However, postchemotherapy RPLND confers no therapeutic benefit if the residual mass contains no viable cells. Therefore, to determine which parameters predict a patient's likelihood of having only necrosis in the residual mass, we retrospectively analyzed clinical parameters of patients who underwent postchemotherapy RPLND. METHODS: Data from 27 patients with metastatic testicular cancer were analyzed. The histology of the primary tumor was seminoma in 11 cases and non-seminoma in 16 cases. All of the patients with non-seminoma showed a normalization of tumor markers after chemotherapy. Analysis of clinical parameters included data for the initial histology, pretreatment tumor marker levels, postchemotherapy retroperitoneal mass size, and the histology of the dissected RPLNs. RESULTS: Histological examination of dissected RPLNs showed residual tumor in 27% of seminoma patients and 38% of non-seminoma patients. In seminoma patients, no viable cells were found in all six patients with pretreatment lactate dehydrogenase (LDH) levels below 7.5 times the upper limit of normal, or in all five of the patients with postchemotherapy RPLNs less than 2.5 cm. In non-seminoma patients, no viable cells were found in nine of 10 patients with pretreatment alpha-fetoprotein (AFP) levels less than 2700 ng/mL, or in eight of nine patients with residual mass less than 2.5 cm. CONCLUSIONS: Both postchemotherapy RPLN mass size and pretreatment tumor marker levels are possible predictors for necrosis of the residual mass in testicular cancer patients. 相似文献
76.
Asystole Following Left Ventricular Pacing 总被引:1,自引:0,他引:1
During biventricular ICD implantation, pacing the epicardial inferior posterior-lateral surface of the left ventricle via the coronary sinus produced asystole. The proposed mechanism is a Bezold-Jarisch reflex manifested by a drop in heart rate and blood pressure through direct C fiber stimulation. (PACE 2004; 27[Pt. I]:815–817) 相似文献
77.
78.
79.
Teruyuki Usuba Yutaka Suzuki Akira Kuramochi Hisao Tajiri Katsuhiko Yanaga 《Digestive endoscopy》2007,19(1):18-21
Background: Buried bumper syndrome (BBS) is a rare complication of percutaneous endoscopic gastrostomy (PEG). Along with the widespread use of the button‐type kit, BBS is encountered frequently. Methods: In the present study, we examined causes and treatments for BBS among 1400 patients who had undergone PEG. Results: The causes of BBS after PEG were classified into two categories: early causes consisted of wound infection, inappropriate size of kit and severe lordosis, while late causes were inappropriate exchange of kit, rough management or weight gain. The treatments for BBS could be determined by the degree of wound infection, fistula and burial of the bumper. Conclusion: We prepared a flowchart for replacement, by which BBS can be managed safely and quickly without surgical or endoscopic intervention. 相似文献
80.
Donald B. Penzien PhD ; Frank Andrasik PhD ; Brian M. Freidenberg PhD ; Timothy T. Houle PhD ; Alvin E. Lake III PhD; Gay L. Lipchik PhD ; Kenneth A. Holroyd PhD ; Richard B. Lipton MD ; Douglas C. McCrory MD ; Justin M. Nash PhD ; Robert A. Nicholson PhD ; Scott W. Powers PhD ABPP ; Jeanetta C. Rains PhD ; David A. Wittrock PhD 《Headache》2005,45(S2):S110-S132
Guidelines for design of clinical trials evaluating behavioral headache treatments were developed to facilitate production of quality research evaluating behavioral therapies for management of primary headache disorders. These guidelines were produced by a Workgroup of headache researchers under auspices of the American Headache Society. The guidelines are complementary to and modeled after guidelines for pharmacological trials published by the International Headache Society, but they address methodologic considerations unique to behavioral and other nonpharmacological treatments. Explicit guidelines for evaluating behavioral headache therapies are needed as the optimal methodology for behavioral (and other nonpharmacologic) trials necessarily differs from the preferred methodology for drug trials. In addition, trials comparing and integrating drug and behavioral therapies present methodological challenges not addressed by guidelines for pharmacologic research. These guidelines address patient selection, trial design for behavioral treatments and for comparisons across multiple treatment modalities (eg, behavioral vs pharmacologic), evaluation of results, and research ethics. Although developed specifically for behavioral therapies, the guidelines may apply to the design of clinical trials evaluating many forms of nonpharmacologic therapies for headache. 相似文献